BALAXI Overzicht aandelen
Balaxi Pharmaceuticals Limited houdt zich bezig met de internationale groothandel in farmaceutische producten, bouwbeslag en FMCG-producten in India en daarbuiten.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Balaxi Pharmaceuticals Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹90.99 |
| 52 Week Hoogtepunt | ₹151.45 |
| 52 Week Laag | ₹80.22 |
| Bèta | 0.64 |
| 11 maand verandering | -8.63% |
| 3 maanden verandering | -20.26% |
| 1 Jaar Verandering | 9.13% |
| 33 jaar verandering | -19.73% |
| 5 jaar verandering | 488.17% |
| Verandering sinds IPO | 3,232.97% |
Recent nieuws en updates
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30
Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Recent updates
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost
Feb 10Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested
May 20A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Feb 03Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Sep 06Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively
Jun 03Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 12Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 27
Rendement voor aandeelhouders
| BALAXI | IN Healthcare | IN Markt | |
|---|---|---|---|
| 7D | 2.0% | 2.7% | 1.8% |
| 1Y | 9.1% | 46.4% | 36.8% |
Rendement versus industrie: BALAXI underperformed the Indian Healthcare industry which returned 47.8% over the past year.
Rendement versus markt: BALAXI underperformed the Indian Market which returned 37.9% over the past year.
Prijsvolatiliteit
| BALAXI volatility | |
|---|---|
| BALAXI Average Weekly Movement | 4.4% |
| Healthcare Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: BALAXI has not had significant price volatility in the past 3 months compared to the Indian market.
Volatiliteit in de loop van de tijd: BALAXI's weekly volatility (4%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1942 | 600 | Ashish Maheshwari | balaxipharma.in |
Balaxi Pharmaceuticals Limited houdt zich bezig met de internationale groothandel in farmaceutische producten, bouwmaterialen en FMCG-producten in India en daarbuiten. Het bedrijf biedt farmaceutische producten aan in verschillende therapeutische gebieden die voornamelijk antibiotica, pijnstillers, anti-malaria en andere behandelen. Het levert ook koekjes en tandpasta.
Balaxi Pharmaceuticals Limited Samenvatting
| BALAXI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹4.63b |
| Inkomsten(TTM) | ₹454.36m |
| Inkomsten(TTM) | ₹2.41b |
10.2x
Koers/Winstverhouding1.9x
P/S-verhoudingIs BALAXI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| BALAXI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹2.41b |
| Kosten van inkomsten | ₹1.27b |
| Brutowinst | ₹1.14b |
| Overige uitgaven | ₹688.12m |
| Inkomsten | ₹454.36m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 8.93 |
| Brutomarge | 47.41% |
| Nettowinstmarge | 18.86% |
| Schuld/Eigen Vermogen Verhouding | 9.6% |
Hoe presteerde BALAXI op de lange termijn?
Bekijk historische prestaties en vergelijking